Latest news

June, 2025, Nantes-based biotech XENOTHERA confirms the value of its LIS22 antibody in the treatment of peripheral T-cell lymphomas (PTCL). The PALT1 clinical trial (NCT06495723) has just passed a new milestone

Read More

May, 2025. XENOTHERA, a French biotechnology company based in Nantes and a pioneer in the development of genetically modified pigs for therapeutic purposes, welcomes the publication of the National Academy of Medicine's report…

Read More

December, 2024. XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials….

Read More

November, 2024. The PALT24 project (Polyspecific Antibodies in Lymphoproliferative T cell disorders) targets a critical onco-hematological disease with a notably low prognosis.

Read More

October, 2024. At the 36th ENA - EORTC - AACR symposium, Firas Bassissi, XENOTHERA CSO, presented highly promising results in pancreatic cancer.

Read More

April, 2024. The AACR Annual Meeting in San Diego was a pivotal...

Read More

March, 2024. FIPO is the first-in-human trial of XON7, the first anti-solid...

Read More

February, 2024. For almost ten years, XENOTHERA has been committed to tackling...

Read More

October 25, 2023. # Download our press release (english version) # Télécharger...

Read More

June 8, 2023. # Download our press release (english version) # Télécharger...

Read More

April 3, 2023. # Download our press release (english version) # Télécharger...

Read More

December 19, 2022. # Download our press alert (english version) # Télécharger...

Read More

December 16,2022. # Download our press release (english version) # Télécharger notre...

Read More

November 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

Read More